Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system.
OBJECTIVE
A "frameless" intrauterine drug delivery system that releases 14 microg/d of levonorgestrel was used to treat nonatypical and atypical endometrial hyperplasia in 12 women.


METHODS
This noncomparative study had up to 3 to 4 years of follow-up.


RESULTS
The cure rate was 100%, as confirmed by repeat endometrial biopsy.


CONCLUSIONS
This method could be considered an alternative to hysterectomy.
Wildemeersch
D
D
Gynecological Research Unit, University Hospital, Knokke and Ghent, Belgium.
Dhont
M
M
D000236:Adenoma / Q000473:pathology; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D016503:Drug Delivery Systems; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D004867:Equipment Design; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage*; D008875:Middle Aged; D014592:Uterine Hemorrhage / Q000188:drug therapy; D014599:Uterus
D000970:Antineoplastic Agents; D016912:Levonorgestrel